Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Most loved VR Game for Wellness: Which Keeps You Dynamic? - 2A Past filled with Old Civilizations: The World's Most established Societies
- 3Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- 4Artemis 2 astronauts head for the moon after make-or-break engine burn (video)
- 5The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- Shipping: The Corridors of Trade and the Coming of Another Period
- The most effective method to Beat Dental Tension and Guarantee Customary Exams
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- Amid Iran war, 53 of Israel's future scientists showcase projects in Jerusalem contest
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- What exactly is the Upside Down in 'Stranger Things'? The wormhole revelation, explained.
- 5 Advancement Developments in Biotechnology
- German police 'cleared path for fascists with batons,' protesters say
- Dental Embed Developments: Upsetting Current Dentistry
